• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Howard Rudy

    2/2/23 4:24:02 PM ET
    $ARAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARAV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    HOWARD RUDY

    (Last) (First) (Middle)
    C/O ARAVIVE, INC., RIVER OAKS TOWER,
    3730 KIRBY DRIVE, SUITE 1200

    (Street)
    HOUSTON TX 77098

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Aravive, Inc. [ ARAV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/01/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.67 02/01/2023 A 400,000(1) (1) 01/31/2033(1) Common Stock 400,000 $0 400,000 D
    Explanation of Responses:
    1. These options vest over three years with 50% vesting on the one-year anniversary of the date of grant and the remaining 50% vesting on a pro rata basis on a monthly basis over a two-year period commencing on the month following the one-year anniversary of the grant date.
    /s/ Abel Svitavsky, Attorney-in-fact 02/02/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ARAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAV

    DatePrice TargetRatingAnalyst
    4/17/2023$12.00Buy
    BTIG Research
    6/3/2022$15.00Buy
    ROTH Capital
    More analyst ratings

    $ARAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Petrini Maria Carolina

      4 - Aravive, Inc. (0001513818) (Issuer)

      4/11/23 4:07:42 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Petrini Maria Carolina

      3 - Aravive, Inc. (0001513818) (Issuer)

      4/11/23 4:07:00 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mcintyre Gail Frances

      4 - Aravive, Inc. (0001513818) (Issuer)

      2/2/23 4:25:16 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Leadership Updates

    Live Leadership Updates

    See more
    • Aravive Appoints Carolina Petrini as Chief Commercial Officer

      HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Carolina Petrini as the Company's new Chief Commercial Officer effective April 10, 2023. Ms. Petrini brings over two decades of experience in developing pre-commercial, launch readiness and commercial strategies, building and leading high-performing commercial teams. "We are delighted to welcome Carolina as our new Chief Commercial Officer," said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. "With her extensive experience in oncology and exception

      4/11/23 7:05:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iTolerance, Inc. Announces Formation of Strategic Advisory Board and Appointment of Inaugural Members

      Establishment of Strategic Advisory Board provides renowned business development, clinical and regulatory leadership and expertise as iTolerance advances its proprietary technologies enabling tissue, organoid or cell therapy without the need for life-long immunosuppressionMIAMI, FL / ACCESSWIRE / January 23, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, today announced the formation of its Strategic Advisory Board and appointments of Wayne Pines, Sigurd Kirk, and Dr. Khemraj Hirani as its inaugural members."The establishm

      1/23/23 11:00:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

      HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chief Medical Officer. Dr. Geller is a medical oncologist with over 30 years of drug development experience leading all aspects of clinical and medical affairs, including commercialization preparedness and launch of novel therapeutics. Dr. Geller will play a critical role in progressing Aravive's portfolio of programs in ovarian, renal and pancreatic cancers. "Dr. Geller is a great addition to the management team as we near completion of the gl

      7/5/22 9:07:03 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aravive, Inc. to Delist from The Nasdaq Stock Market

      HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market ("Nasdaq")  and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and suspend its public reporting obligations. As previously disclosed, at the Company's 2023 annual stockholder's meeting, the stockholders of the Company approved effecting a transfer and assignment of all or substantially all of the Company's assets to an assignee for the benefit

      1/17/24 4:09:41 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

      Trial did not meet primary endpoint of progression-free survivalCash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023 HOUSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. The trial did not show any differen

      8/2/23 4:01:00 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

      HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company's ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell carcinoma (ccRCC) and pancreatic adenocarcinoma (PDAC). Presentation Details: Title:Phase 1b/2 Study of Batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in Combination with Cabozantinib (Cabo)

      7/28/23 7:05:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Aravive Inc.

      15-12G - Aravive, Inc. (0001513818) (Filer)

      2/8/24 7:00:50 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aravive Inc.

      EFFECT - Aravive, Inc. (0001513818) (Filer)

      2/2/24 12:15:24 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aravive Inc.

      EFFECT - Aravive, Inc. (0001513818) (Filer)

      2/2/24 12:15:15 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research resumed coverage on Aravive with a new price target

      BTIG Research resumed coverage of Aravive with a rating of Buy and set a new price target of $12.00

      4/17/23 9:01:46 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH Capital initiated coverage on Aravive with a new price target

      ROTH Capital initiated coverage of Aravive with a rating of Buy and set a new price target of $15.00

      6/3/22 9:00:32 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Aravive with a new price target

      BTIG Research initiated coverage of Aravive with a rating of Buy and set a new price target of $26.00

      3/15/21 8:09:54 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aravive Inc. (Amendment)

      SC 13G/A - Aravive, Inc. (0001513818) (Subject)

      2/14/24 4:21:51 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aravive Inc. (Amendment)

      SC 13G/A - Aravive, Inc. (0001513818) (Subject)

      2/14/24 10:24:11 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aravive Inc. (Amendment)

      SC 13G/A - Aravive, Inc. (0001513818) (Subject)

      2/9/24 5:14:55 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Financials

    Live finance-specific insights

    See more
    • Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma

      7 of 16 (44%) patients achieved best overall response of partial responseConfirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up14 of 16 (88%) patients demonstrated tumor decrease from baselineBatiraxcept has been well-tolerated with no dose-limiting toxicitiesConference call and webcast today at 8:30 a.m. ET HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patie

      11/12/21 7:00:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

      3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been generally well-tolerated with no dose-limiting toxicitiesAravive to host conference call and webcast on November 12 at 8:30 a.m. ET to discuss updated data HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (

      11/9/21 8:00:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care